A multi-center randomized prospective study on the treatment of infant bronchiolitis with interferon α1b nebulization

• DOI: 10.1371/journal.pone.0228391
• Publication Date: 2020-02-21T18:29:35Z
• Authors: Lina Chen; Mingfang Shi; Quanmin Deng; Wenjun Liu; Qin Li; Piao Ye; Xiahui Yu; Benjin Zhang; Yuxia Xu; Xiaolan Li; Yao Yang; Min Li; Yi Yan; Zhe Xu; Jing Yu; Long Xiang; Xiaojun Tang; Guangping Wan; Qiang Cai; Li Wang; Bo Hu; Liang Xie; Gen Li; Lunyan Xie; Xiaoyun Liu; Chunyan Liu; Li Li; Lijie Chen; Xiaobin Jiang; Yana Huang; Si Wang; Jiang Guo; Yan Shi; Li Li; Xiaofang Wang; Zhiyong Zhao; Yan Li; Yanru Liu; Qiang Fu; Yan Zeng; Yan Zou; Dingyuan Liu; Deyun Wan; Tao Ai; Hanmin Liu
• Keywords: Male; Science; Nebulizers and Vaporizers; Q; R; Infant; Interferon-alpha; Antiviral Agents; 3. Good health; Hospitalization; Recurrence; Case-Control Studies; Administration, Inhalation; Medicine; Bronchiolitis; Humans; Female; Prospective Studies; Research Article; Respiratory Sounds

Background The respiratory syncytial virus (RSV) is the main cause of bronchiolitis in infants and interferon (IFN) α a commercial antiviral drug. nebulization IFN α1b could be viable treatment method. In this study, therapeutic effects safety delivery via infant were investigated multi-center prospective study. Methods findings Bronchiolitis patients admitted to 22 hospitals who met inclusion criteria enrolled randomly allocated four groups: control, Intramuscular Injection, Nebulization 1 (1 μg/kg), 2 (2 μg/kg) groups. All observed for 7 days. different doses modes evaluated. Coughing severity change, as scored by researchers parents, between days 3 was significantly control Lowell wheezing score change 5 There no significant differences among groups regarding number consecutive with fever, three-concave sign, fatigue sleepiness, loss appetite. cases severe complications, recurrence regression mental status. Conclusions IFN-α1b more effectively alleviate coughing bronchiolitis. had advantages shortening duration alleviating coughing.